uniQure (NASDAQ:QURE) Stock Price Down 5.1% – What’s Next?

uniQure N.V. (NASDAQ:QURE) shares traded down 5.1% on Friday . The stock traded as low as $21.47 and last traded at $21.5790. 807,901 shares were traded during trading, a decline of 64% from the average session volume of 2,242,114 shares. The stock had previously closed at $22.74.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. The Goldman Sachs Group decreased their target price on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. William Blair reaffirmed a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. UBS Group set a $95.00 target price on uniQure in a research report on Thursday, September 25th. Chardan Capital restated a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research report on Thursday. Finally, Benchmark reissued a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $64.42.

uniQure Stock Performance

The stock’s 50-day moving average is $45.23 and its 200 day moving average is $26.05. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The firm has a market cap of $1.30 billion, a P/E ratio of -4.77 and a beta of 0.59.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. On average, research analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 226,316 shares of the business’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares in the company, valued at approximately $27,009,282.84. The trade was a 25.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Christian Klemt sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the transaction, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at $11,975,150. This represents a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 314,560 shares of company stock worth $12,362,568. 4.79% of the stock is currently owned by insiders.

Hedge Funds Weigh In On uniQure

Large investors have recently modified their holdings of the business. Vestal Point Capital LP increased its position in shares of uniQure by 58.4% in the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after acquiring an additional 1,767,572 shares during the last quarter. Avoro Capital Advisors LLC grew its stake in uniQure by 22.6% in the third quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock valued at $259,422,000 after purchasing an additional 819,444 shares in the last quarter. Aberdeen Group plc increased its position in shares of uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares during the last quarter. Nantahala Capital Management LLC raised its stake in shares of uniQure by 3.8% during the 1st quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock worth $29,213,000 after purchasing an additional 101,598 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of uniQure in the 2nd quarter valued at approximately $29,217,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.